Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115409 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Pietro De Placido und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy; Department of Medical Oncology, Dana-Farber Cancer Institute, Bost…. Hauptthemen laut MEDLINE: Breast Neoplasms, Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli Federico II.
Abstract (Originalsprache)
BACKGROUND: Hormone receptor-positive (HR+)/HER2-negative (HER2-) early-stage breast cancers (EBC) are treated with adjuvant endocrine therapy (ET), with chemotherapy (CT) reserved for high-risk cases. Obesity is linked to increased recurrence risk. The Oncotype DX® assay predicts prognosis and CT benefit. The PRO BONO study evaluated Oncotype DX test's impact on treatment decisions and explored associations between genomic risk, tumor features, and patient metabolic profiles. MATERIALS AND METHODS: Patients with HR+ /HER2-EBC undergoing Oncotype DX testing were enrolled. Body mass index (BMI), tumor characteristics (ER, PR, Ki67, grading, size, nodal status), a large panel of metabolic analytes, and Oncotype DX Recurrence Score® (RS) results were collected. Treatment recommendations (ET vs CT-ET) were recorded pre- and post-Oncotype DX, and concordance was determined using Cohen's Kappa. Associations were tested using Chi-Square test and Spearman Correlation. RESULTS: Of the 248 EBC patients (2019-2021), Oncotype DX testing reduced CT use by 47.7 %. Higher RS positively correlated with serum triglycerides and inversely with GIP (all p 148.85pg/ml) were independently associated with increased odds of having larger tumor size (>2 cm). CONCLUSIONS: Recurrence Score result significantly impacts treatment decisions in HR+ /HER2-EBC. RS result was not associated with BMI, although unfavorable metabolic profiles and obesity-related markers correlated with larger tumors. These findings highlight the need to further investigate the link between metabolic profiles and breast cancer biology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
- Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy; Clinical and Translational Oncology, Scuola Superiore Meridionale, Naples, Italy.
- Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
- Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy; Clinical and Translational Oncology, Scuola Superiore Meridionale, Naples, Italy; Department of Clinical…
- Department of Translational Medicine, University Federico II, Naples, Italy.
- Institute of Endotypes in Oncology, Metabolism and Immunology "G. Salvatore" - National Research Council (IEOMI-CNR), Naples, Italy.
Förderung
- Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli Federico II
Zitieren
APA
De Placido, P., Di Rienzo, R., Pietroluongo, E., Martinelli, C., Tafuro, M., Formisano, P., D'Esposito, V., Poggio, F. B., Ruelle, T., Cardinali, B., Di Lauro, V., Buono, G., Caputo, R., Buonaiuto, R., Caltavituro, A., Rocco, P., Porciello, G., De Laurentiis, M., Del Mastro, L., …, & Giuliano, M. (2025). Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115409
Vancouver
De Placido P, Di Rienzo R, Pietroluongo E, Martinelli C, Tafuro M, Formisano P, et al. Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115409
BibTeX
@article{DePlacido2025,
author = {De Placido, Pietro and Di Rienzo, Rossana and Pietroluongo, Erica and Martinelli, Claudia and Tafuro, Margherita and Formisano, Pietro and D'Esposito, Vittoria and Poggio, Francesca Benedetta and Ruelle, Tommaso and Cardinali, Barbara and Di Lauro, Vincenzo and Buono, Giuseppe and Caputo, Roberta and Buonaiuto, Roberto and Caltavituro, Aldo and Rocco, Paola and Porciello, Giuseppe and De Laurentiis, Michelino and Del Mastro, Lucia and Vernieri, Claudio and Veneziani, Bianca Maria and Bianco, Roberto and Crispo, Anna and De Angelis, Carmine and Arpino, Grazia and Giuliano, Mario},
title = {Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115409}
}
EUVIMED